Hospital admissions due to infections in the national population of people with multiple sclerosis on disease-modifying therapies: Real-world data from NHS England

被引：0
|
作者：
Garjani, Afagh [1 ,2 ]
Osborne, Nick [3 ]
Law, Graham [4 ]
Nightingale, Matthew [3 ]
Evangelou, Nikos [1 ,2 ]
机构：
[1] Univ Nottingham, Sch Med, Mental Hlth & Clin Neurosci Acad Unit, Nottingham, England
[2] Nottingham Univ Hosp NHS Trust, Neurol Clin, Nottingham, England
[3] NHS Arden & Greater East Midlands Commissioning S, Leicester, Leics, England
[4] Univ Lincoln, Sch Hlth & Social Care, Coll Hlth & Sci, Lincoln, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O091/2549
引用
收藏
页码：86 / 87
页数：2
相关论文
共 50 条
  • [31] Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry
    Bossart, Jonas
    Kamm, Christian P.
    Kaufmann, Marco
    Stanikic, Mina
    Puhan, Milo A.
    Kesselring, Juerg
    Zecca, Chiara
    Gobbi, Claudio
    Rapold, Irene
    Kurmann, Roland
    Ammann, Sabin
    von Wyl, Viktor
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 60
  • [32] Real-World Monitoring Costs Associated with Initiation of Disease-Modifying Therapy Among Patients with Multiple Sclerosis
    Lage, Maureen L.
    Wu, Ying
    NEUROLOGY, 2017, 88
  • [33] Identifying and Characterizing Fatigue in Patients Diagnosed with Multiple Sclerosis on Disease-Modifying Therapies Using Real World Evidence
    Cole, M.
    Le, H.
    Verma, S.
    Keenan, A.
    Leist, T.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 92 - 92
  • [34] Real-world cost of treatment for multiple sclerosis patients initiating and receiving infused disease-modifying therapies per recommended label in the United States
    Nicholas, Jacqueline
    Halpern, Rachel
    Ziehn, Marina
    Peterson-Brandt, Jesse
    Leszko, Michael
    Deshpande, Chinmay
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (08) : 885 - 893
  • [35] Assessing the Expanded Disability Status Scale in Secondary Progressive Multiple Sclerosis Patients Treated with Disease-Modifying Therapies within a Large, Representative Real-World Multiple Sclerosis Registry
    Brecht, T.
    Friedler, H.
    Mulder, K.
    Paulus, J.
    Su, Z.
    Curhan, G.
    Starzyk, K.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 104 - 104
  • [36] Switching between disease-modifying therapies in patients with spinal muscular atrophy: real-world data collected from the RESTORE Registry
    Servais, L.
    Day, J.
    De Vivo, D.
    Kirschner, J.
    Mercuri, E.
    Muntoni, F.
    Shieh, P.
    Tizzano, E.
    Desguerre, I.
    Quijano-Roy, S.
    Saito, K.
    Droege, M.
    Dabbous, O.
    Shah, A.
    Anderson, F.
    Finkel, R.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S97 - S97
  • [37] Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy
    Ziemssen, T.
    Kurzeja, A.
    Haas, J.
    Alexander, J.
    Driessen, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 547 - 548
  • [38] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Prosperini, Luca
    Haggiag, Shalom
    Ruggieri, Serena
    Tortorella, Carla
    Gasperini, Claudio
    CNS DRUGS, 2023, 37 (10) : 915 - 927
  • [39] Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies
    Luca Prosperini
    Shalom Haggiag
    Serena Ruggieri
    Carla Tortorella
    Claudio Gasperini
    CNS Drugs, 2023, 37 : 915 - 927
  • [40] REAL WORLD ADHERENCE, PERSISTENCE, RELAPSE AND MULTIPLE SCLEROSIS SYMPTOMS AMONG PATIENTS TREATED WITH ORAL DISEASE-MODIFYING THERAPIES
    Leist, T.
    Le, H.
    Verma, S.
    Cole, M.
    Afolabi, M.
    Tsai, W. L.
    Keenan, A.
    VALUE IN HEALTH, 2021, 24 : S13 - S13
12345